The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study.
 
Andrew X. Zhu
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Eisai; Exelixis; Sanofi
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Chia-Jui Yen
No Relationships to Disclose
 
Masatoshi Kudo
No Relationships to Disclose
 
Ronnie Tung-Ping Poon
No Relationships to Disclose
 
Davide Pastorelli
No Relationships to Disclose
 
Jean-Frédéric Blanc
Consulting or Advisory Role - Lilly
 
Hyun Cheol Chung
Consulting or Advisory Role - Celltrion; Lilly
 
Ari David Baron
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Lilly
 
Tulio Eduardo Flesch Pfiffer
Consulting or Advisory Role - Lilly
Speakers' Bureau - Bayer; Lilly
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Bayer
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly; Merck Serono; Nippon Boehringer Ingelheim; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Pfizer; Sceti Medical Labo; Siemens; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Katerina Kubackova
Speakers' Bureau - Roche
Travel, Accommodations, Expenses - Bayer; Pfizer; Roche; Sanofi
 
Jorg Trojan
Consulting or Advisory Role - Bayer; Lilly
Speakers' Bureau - Bayer
 
Javier Sastre
Speakers' Bureau - Bayer; Lilly; Merck; MSD; Roche; Sanofi
 
Ian Chau
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Merck Serono; Sanofi
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Shao-Chun Chang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Paolo Abada
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Lilly (Inst)
 
Ling Yang
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Yanzhi Hsu
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Joon Oh Park
Research Funding - GlaxoSmithKline; Sanofi